SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 203 filers reported holding SAGE THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.23 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $442,462 | -57.2% | 11,601 | -56.1% | 0.01% | -61.5% |
| Q3 2022 | $1,034,000 | +4.2% | 26,413 | -14.0% | 0.03% | 0.0% |
| Q2 2022 | $992,000 | -51.1% | 30,700 | -49.9% | 0.03% | -45.8% |
| Q1 2022 | $2,029,000 | -37.9% | 61,293 | +6.6% | 0.05% | -54.3% |
| Q2 2021 | $3,266,000 | +310.8% | 57,500 | +441.4% | 0.10% | +250.0% |
| Q1 2021 | $795,000 | +19.9% | 10,621 | +38.6% | 0.03% | +20.0% |
| Q4 2020 | $663,000 | -22.7% | 7,664 | -45.4% | 0.02% | -51.9% |
| Q3 2020 | $858,000 | -14.8% | 14,034 | -42.0% | 0.05% | -24.6% |
| Q2 2020 | $1,007,000 | +66.2% | 24,209 | +14.7% | 0.07% | +38.0% |
| Q1 2020 | $606,000 | -63.0% | 21,113 | -6.9% | 0.05% | -64.8% |
| Q4 2019 | $1,637,000 | +358.5% | 22,683 | +895.7% | 0.14% | +358.1% |
| Q2 2018 | $357,000 | -40.7% | 2,278 | -39.0% | 0.03% | -56.3% |
| Q1 2018 | $602,000 | -6.5% | 3,735 | -4.4% | 0.07% | -24.5% |
| Q4 2017 | $644,000 | – | 3,908 | – | 0.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sio Capital Management, LLC | 179,200 | $29,516,000 | 16.65% |
| TRV GP II, LLC | 547,916 | $90,247,000 | 16.25% |
| Opus Point Partners Management, LLC | 71,000 | $11,694,000 | 10.12% |
| Casdin Capital, LLC | 250,000 | $41,178,000 | 10.03% |
| RA Capital Management | 455,173 | $74,972,000 | 6.27% |
| Crawford Lake Capital Management, LLC | 154,278 | $25,411,000 | 6.00% |
| Palo Alto Investors LP | 810,806 | $133,548,000 | 5.75% |
| GREAT POINT PARTNERS LLC | 200,000 | $32,942,000 | 5.62% |
| BB BIOTECH AG | 1,042,439 | $171,700,000 | 4.84% |
| Crawford Lake Capital Management, LLC | 92,300 | $15,203,000 | 3.59% |